The Norwegian Adult Achondroplasia Study

Sponsor
Sunnaas Rehabilitation Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03780153
Collaborator
(none)
50
1
64
0.8

Study Details

Study Description

Brief Summary

The study aims to investigate the Norwegian adult achondroplasia population regarding degree and extent of symptoms and clinical manifestations and how this population manages in daily life, including demographics, physical function, and work participation.

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention

Detailed Description

The present study aims to investigate the degree and extent of spinal stenosis, chronic pain, sleep apnoea, impaired hearing, cardiovascular risk factors and body composition in Norwegian adults with achondroplasia. The study will also explore these factors' impact on physical function, ability to perform daily activities, work participation and needs for assistive devices and social benefits. The study is conducted in collaboration with the Norwegian Restricted Growth Association, and TRS National Resource Centre for Rare Disorders, Sunnaas Rehabilitation Hospital, Lovisenberg Hospital and Oslo University Hospital.

Study Design

Study Type:
Observational
Actual Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
The Norwegian Adult Achondroplasia Study
Actual Study Start Date :
Mar 1, 2017
Actual Primary Completion Date :
Mar 31, 2019
Anticipated Study Completion Date :
Jun 30, 2022

Outcome Measures

Primary Outcome Measures

  1. Describe the prevalence of medical complications in adults with achondroplasia [2 years]

    Describe prevalence of medical complications in a cohort of Norwegian adults with achondroplasia using interview, clinical examination and review of medical records. Data on spinal stenosis will be obtained by face-to-face interview, clinical examination, and review of medical charts including MRI-scans. Assessment of sleep apnoea will include an overnight sleep registration (polygraphy). Hearing will be assessed by standardized examination including audiometry, tympanometry and impedance measurements

  2. Describe prevalence of cardiovascular risk factors in adults with achondroplasia, and investigate body composition. [2 years]

    Cardiovascular risk factors, including smoking habits and blood pressure, will be recorded by interview and clinical examination, and will also include a fasting blood sample for lipids, glucose, HbA1C, thyroid, kidney and liver function tests. Body composition will be assessed by anthropometric measures (height in cm, weight in kg, waist circumference in cm, and hip circumference in cm), BMI will be calculated, and body fat content and distribution will be assessed by using MRI.

  3. Demographics and activity of daily living (ADL), education and work participation [2 years]

    Data on age, gender, education level, work participation, needs for assistive devices and social benefits will be obtained by interview. Assessment of ADL will be obtained by clinical interview and by use of The Health Assessment Questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Residents of Norway

  • Aged 16 years or older

  • Clinical and genetic diagnosis of achondroplasia

  • Speak and understand the Norwegian language.

Exclusion Criteria:
  • Severe cognitive deficits, mental illness or substance abuse

  • Having a medical condition making them unable to participate in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sunnas Rehabilitation Hospital Nesoddtangen Akershus Norway 1450

Sponsors and Collaborators

  • Sunnaas Rehabilitation Hospital

Investigators

  • Study Director: Vegard Strom, Phd, Sunnaas Rehabilitation Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sunnaas Rehabilitation Hospital
ClinicalTrials.gov Identifier:
NCT03780153
Other Study ID Numbers:
  • 2019/FO249324
First Posted:
Dec 19, 2018
Last Update Posted:
Dec 15, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 15, 2021